Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms

A retrospective review of 42 patients with MPNs, including blast-phase (BP) and accelerated-phase (AP) disease and high-risk myelofibrosis (MF-HR), found that decitabine alone or in combination with ruxolitinib may have clinical benefit in this patient population when initiated before progression to blast-phase disease. Median overall survival for MPN-BP patients was 2.6 months and 6.7 months for those who received ≥ 2 cycles of decitabine therapy.